We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Ingestible Balloon Helps Patients Lose Weight

By HospiMedica International staff writers
Posted on 04 Oct 2016
An ingestible intragastric balloon system facilitates weight loss in obese adults who failed to lose weight through diet and exercise.

The Obalon system consists of a balloon folded inside a capsule that is swallowed by the patient, with no sedation or anesthesia required. More...
Once the balloon reaches the stomach, it is remotely inflated via an attached micro-catheter that is subsequently removed, leaving behind a buoyant balloon with a volume of 250cc (about the size of a small orange) that weighs less than six grams. Over the following three months of treatment, two additional balloons are swallowed and inflated, bringing the total maximum displaced volume to750cc.

The nonsurgical weight loss system is fully reversible throughout the course, and at the end of the six-month treatment period, all three balloons are mandatorily removed via endoscopy under conscious sedation. The system is intended for use as an adjunct to a moderate intensity diet and to a behavior modification program. The Obalon balloon system is a product of Obalon (Carlsbad, CA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

“We’re excited to bring this novel technology to the approximately 70 million adults in the United States who are struggling with obesity. For physicians, we believe that the Obalon technology represents an important new option for both their practices and their patients who are obese and looking to lose weight,” said Andy Rasdal, CEO of Obalon. “I’d also like to recognize the FDA for their efficient and interactive review of our product, which represents another option for physicians and patients in the battle against the obesity epidemic.”

“The clinical trial design for the Obalon balloon system was highly rigorous and the system demonstrated a favorable safety profile,” said Shelby Sullivan, MD, director of the gastroenterology bariatric and metabolic program at the University of Colorado School of Medicine (Aurora, USA). “We were also pleased to see that patients tolerated the administrations of the Obalon balloon remarkably well, with no recovery time needed. This is in contrast to other currently approved intragastric balloon devices, where most patients cannot immediately return to normal activities.”

Related Links:
Obalon



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image:The biotechnology market in the GCC is projected to reach $2.6 billion by 2028, with the UAE and Saudi Arabia leading the growth in the region (Photo Courtesy of Infroma Markets)

WHX in Dubai (formerly Arab Health) to debut specialised Biotech & Life Sciences Zone as sector growth accelerates globally

World Health Expo (WHX) in Dubai, formerly Arab Health, which takes place from 9-12 February 2026 at the Dubai Exhibition Centre (DEC), has officially announced the launch of a new dedicated Biotech &... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.